Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

September 22, 2015 updated by: John Treanor, University of Rochester

Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children

A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09 influenza vaccine (IIV) or IIV followed by LAIV separated by 28 days. Children with prior vaccination or natural infection with novel H1N1 influenza will be excluded. Randomization will be stratified by pre-existing HAI titers to the previous winter's seasonal H1N1 A/Brisbane/57/07 reference virus.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

The study will be conducted as a randomized, prospective, open-label evaluation of the clinical tolerability, vaccine virus shedding, and serum and mucosal antibody response to vaccination with either live monovalent novel H1N1 influenza vaccine (LAIV) or monovalent inactivated novel H1N1 influenza vaccine (IIV) in healthy children between the ages of 4 and 9 years. Children will be screened for antibody to A/Brisbane/57/07 (H1N1) and A/California/07/09 (H1N1) prior to randomization. Children with evidence of prior exposure to the 2009 pandemic H1N1 virus will be excluded. Those with antibodies to A/Brisbane/57/07 (H1N1) will be stratified by preexisting antibody. Vaccine will be administered on days 0 and 28.

Safety of vaccination will be assessed using symptoms collected by parents for 7 days after each dose of vaccine. Serum will be obtained prior to and on day 28 following each dose of vaccine and assessed for antibody by HAI, ELISA, B-cell ELISPOT and neutralization techniques. Nasal secretions will be obtained by nasal aspiration prior to and on day 28 after each dose and assessed for HA-specific IgA antibody by ELISA. Nasal swabs will be obtained on days 2, 4, and 7 after each dose of live vaccine and assessed for the presence and magnitude of vaccine virus shedding of the live attenuated vaccine by rtRT-PCR and TCID50 on MDCK cells.

Study Type

Interventional

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center, Vaccine Research Unit Room 3-5000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 years to 9 years (CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged between 4 and 9 years, inclusive.
  • Pre-vaccination serum HAI titer to A/California/07/09 of 8 or less
  • No prior history of laboratory documented infection with novel H1N1 virus or immunization with novel H1N1 vaccine.
  • in good health, as determined by: vital signs (heart rate <140 bpm; blood pressure: systolic ≥ 90 mm Hg and ≤140 mm Hg; diastolic ≤ 90 mm Hg; oral temperature <100.0ºF); medical history; and targeted physical examination, when necessary, based on medical history. Stable medical condition is defined as: no recent increase in prescription medication, dose, or frequency of medication in the last 3 months and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months.
  • subject/parents are able to understand and comply with the planned study procedures, including being available for all study visits.
  • subject/parents have provided informed consent prior to any study procedures. (An assent will be obtained for all children 6 years and older)

Exclusion Criteria:

  • a previous history of vaccination against novel H1N1 virus or a laboratory documented history of previous novel H1N1 infection.
  • History of egg allergy or allergy to other components of vaccine.
  • History of wheezing.
  • immunosuppressed as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy.
  • has an active neoplastic disease.
  • has long-term (greater than 2 weeks) use of oral or parenteral steroids, or high-dose inhaled steroids (>800 mg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).
  • received immunoglobulin or another blood product within the 3 months prior to enrollment in this study.
  • has received an inactivated vaccine within the 2 weeks or a live vaccine within the 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days (or 56 days for vaccine naïve recipients).
  • has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. These conditions include chronic conditions recognized as risk factors for influenza complications or as contraindications for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment.
  • has an acute illness or an oral temperature greater than 99.9 degrees F (37.7 degrees C) within 3 days prior to enrollment or vaccination. Subjects who had an acute illness that was treated symptoms resolved are eligible to enroll as long as treatment is completed and symptoms resolve > 3 days prior to enrollment.
  • is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive another experimental agent during participation in this study, or intends to donate blood during the study period.
  • has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
  • has a known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
  • has a previous history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccination.
  • has any condition that the principal investigator (PI) believes may interfere with successful completion of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: LAIV/LAIV
Biological: Live Attenuated H1N1 Influenza Vaccine
0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
Other Names:
  • Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal
ACTIVE_COMPARATOR: IIV/IIV
Biological: Influenza A (H1N1) 2009 Monovalent Vaccine
0.5 ml IM, 2 doses given 28 days apart
Other Names:
  • Influenza vaccine
ACTIVE_COMPARATOR: IIV/LAIV
Biological: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
Other Names:
  • Influenza Vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C
Time Frame: nasal swabs obtained at days 2 post vaccination
nasal swabs obtained at days 2 post vaccination
The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C
Time Frame: nasal swab at 4 days post vaccination
nasal swab at 4 days post vaccination
The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C
Time Frame: nasal swab obtained at 7 days post vaccination
nasal swab obtained at 7 days post vaccination

Secondary Outcome Measures

Outcome Measure
Time Frame
The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR
Time Frame: swabs will be obtained on day 2 post vaccination
swabs will be obtained on day 2 post vaccination
The frequency and magnitude of serum hemagglutination-inhibition (HAI), ELISA, and neutralizing antibody response to vaccine
Time Frame: at day 28
at day 28
The frequency and magnitude of hemagglutinin-specific mucosal IgA response assessed by ELISA on nasal secretions
Time Frame: day 28
day 28
The frequency and magnitude of antibody secreting cell and memory B cells developing after vaccination
Time Frame: on day 7
on day 7
Development of specific local and systemic symptoms occuring after vaccine
Time Frame: for 7 days post each vaccination
for 7 days post each vaccination
The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR
Time Frame: swab obtained at day 4 post vaccination
swab obtained at day 4 post vaccination
The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR
Time Frame: swab obtained at day 7 post vaccination
swab obtained at day 7 post vaccination
The frequency and magnitude of serum hemagglutination-inhibition (HAI), ELISA, and neutralizing antibody response to vaccine
Time Frame: at day 56
at day 56
The frequency and magnitude of hemagglutinin-specific mucosal IgA response assessed by ELISA on nasal secretions
Time Frame: at day 56
at day 56
The frequency and magnitude of antibody secreting cell and memory B cells developing after vaccination
Time Frame: on day 35
on day 35

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Rochester

Collaborators

National Institutes of Health (NIH)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (ACTUAL)

September 1, 2010

Study Completion (ACTUAL)

September 1, 2010

Study Registration Dates

First Submitted

March 30, 2010

First Submitted That Met QC Criteria

April 1, 2010

First Posted (ESTIMATE)

April 2, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

September 24, 2015

Last Update Submitted That Met QC Criteria

September 22, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • URMC 09-007

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on 2009 H1N1 Influenza

Clinical Trials on Live Attenuated H1N1 Influenza Vaccine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe